Xiaohui Sun

Dr. Xiaohui Sun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Frontiers in Neuroscience
Verified
Journal Article
Open access
Xiaohui SunXiaohui Sun
Xiaohui Sun
LXLi Xue
Li Xue
ZWZechen Wang
Zechen Wang
XAXie Anmu
Xie Anmu
Gastrointestinal (GI) symptoms represented by constipation were significant non-motor symptoms of Parkinson’s disease (PD) and were considered early manifestations and aggravating factors of the disease. This paper reviewed the research progress of the mechanism of the gut-brain axis (GBA) in PD and discussed the roles of α-synuclein, gut microbiota, immune inflammation, neuroendocrine, mitochondrial autophagy, and environmental toxins in the mechanism of the GBA in PD. Treatment of PD based on the GBA theory has also been discussed, including (1) dietary therapy, such as probiotics, vitamin therapy, Mediterranean diet, and low-calorie diet, (2) exercise therapy, (3) drug therapy, including antibiotics; GI peptides; GI motility agents, and (4) fecal flora transplantation can improve the flora. (5) Vagotomy and appendectomy were associated but not recommended.

7 January 2023 in Neuroscience Letters
Verified
Journal Article
Closed access
Xiaohui SunXiaohui Sun
Xiaohui Sun
QTQing Tian
Qing Tian
ZYZhengjie Yang
Zhengjie Yang
YLYumei Liu
Yumei Liu
CLChengqian Li
Chengqian Li
XAXie Anmu
Xie Anmu

23 January 2024 in Clinical and Translational Science
Verified
Journal Article
Open access
Xiaohui SunXiaohui Sun
Xiaohui Sun
KDKaixin Dou
Kaixin Dou
LXLi Xue
Li Xue
YXYijie Xie
Yijie Xie
YYYong Yang
Yong Yang
XAXie Anmu
Xie Anmu
The Parkinson's Progression Marker Initiative (PPMI) aims to identify biomarkers for Parkinson's disease (PD) risk, onset, and progression. This study focuses on the G2019S missense mutation in the LRRK2 gene, which is associated with hereditary and sporadic PD. Utilizing data from the PPMI database, we conducted an analysis of baseline clinical characteristics, as well as serum and cerebrospinal fluid levels in two groups: patients with PD with the G2019S mutation (PD + G2019S) and patients with PD without the mutation (PD‐G2019S). Multiple linear regression and longitudinal analysis were performed, controlling for confounding factors. Compared to the PD‐G2019S group, the PD + G2019S group showed more obvious initial motor dysfunction—higher baseline Movement Disorder Society‐Sponsored Revision of the Unified Parkinson Disease Rating Scale (MDS‐UPDRS) scores (false discovery rate [FDR]‐adjusted p < 0.001), but progressed more slowly. Mechanism of Coordinated Access and activities of daily living (ADL) scores were lower at baseline (FDR‐adjusted p < 0.001), whereas Scales for Outcomes of Parkinson's Disease (SCOPA)‐Thermoregulatory (FDR‐adjusted p = 0.015) scores were higher, emphasizing the increase of non‐motor symptoms associated with LRRK2‐G2019S mutation. During the follow‐up period, the motor and non‐motor symptoms changed dynamically with time, and there were longitudinal differences in the scores of MDS‐UPDRS (FDR‐adjusted PI = 0.013, PII = 0.008, PIV < 0.001), Questionnaire for Impulsive‐Compulsive Disorders in Parkinson's Disease (FDR‐adjusted p = 0.027), SCOPA‐Thermoregulatory (FDR‐adjusted p = 0.021), and ADL (FDR‐adjusted p = 0.027) scale scores. PD associated with the LRRK2 G2019S mutation demonstrated more severe symptoms at baseline but slower progression. Motor complications and thermoregulatory disorders were more pronounced.

25 March 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
FNFeng Ning
Feng Ning
Xiaohui SunXiaohui Sun
Xiaohui Sun
BGBing Ge
Bing Ge
SLShunping Li
Shunping Li
BHBinghui Hou
Binghui Hou
DZDong Zhang
Dong Zhang
Backgrounds: Obesity is increasing in adolescents in China. However, the awareness of obesity and prevention on related risk factors were not well known. We aim to assess the effectiveness of short-term health education intervention on obesity in Chinese adolescents.Methods: In this study, 42 primary and secondary schools from Qingdao were randomly divided into the education and control groups. A total of 11,739 adolescents was included in the current study. The logistic regression was employed to assess odds ratio (OR) of education intervention on overweight and obesity prevalence adjusting for covariates.Results: The baseline prevalence of overweight and obesity was significantly higher in urban than in rural areas and in boys than in girls. After 1 year lifestyle intervention, the proportion of students with awareness of obesity was higher, meanwhile age-adjusted mean values of weight, body mass index, duration of watching TV and doing homework were lower in education group than control group. The corresponding figures were 43.6 [95% CI (confidence intervals); 43.3–43.9] kg versus 44.3 (95% CI; 44.0–44.6) kg, 18.6 (95% CI; 18.5–18.7) kg/m2 versus 18.9 (95% CI; 18.8–19.1) kg/m2, 1.3 (95% CI; 1.2–1.3) hours/d versus 1.4 (95% CI; 1.3–1.4) hours/d, and 1.5 (95% CI; 1.4–1.5) hours/d versus 1.8 (95% CI, 1.7–1.8) hours/d. The multivariable adjusted OR for combined prevalence of overweight and obesity was 0.85 (95% CI, 0.76–0.96) in education group as compared with control group.Conclusion: Short-term health education intervention results in significantly higher reductions in obesity parameters and improvement in awareness in Chinese adolescents.

20 July 2023 in Neuroscience Letters
Verified
Journal Article
Closed access
QTQing Tian
Qing Tian
Xiaohui SunXiaohui Sun
Xiaohui Sun
CLChengqian Li
Chengqian Li
YYYong Yang
Yong Yang
BHBinghui Hou
Binghui Hou
XAXie Anmu
Xie Anmu

25 April 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
LXLu Xu
Lu Xu
YZYating Zhao
Yating Zhao
YLYifan Liang
Yifan Liang
CBCouronne Adoummadji Benaindo
Couronne Adoummadji Benaindo
Xiaohui SunXiaohui Sun
Xiaohui Sun
JWJian Wu
Jian Wu
Imbalance of immune homeostasis in vascular endothelial cells (VECs) plays a crucial role in blood–brain barrier (BBB) disruption and secondary brain injury following ischemic stroke (IS). Downregulation of CD151 in VECs has demonstrated significant therapeutic effects in IS. However, the role of CD151 in endothelial immune homeostasis remains unclear, and no noninvasive delivery system currently targets CD151 within the ischemic region. Therefore, we aimed to establish an exosome (Exo)-based delivery system capable of targeting and suppressing CD151 in ischemia-injured VECs and to explore the effects and molecular mechanisms of CD151 in regulating VEC immune homeostasis and BBB repair after IS. Exosomes were isolated from oxygen–glucose deprivation (OGD)-preconditioned primary brain microvascular endothelial cells (BMVECs). The Exo-siCD151 system was established by loading siCD151 via electroporation. In vitro, Exo-siCD151 was applied to BMVECs to evaluate cellular targeting and its role in regulating endothelial immune homeostasis. In vivo, Exo-siCD151 was administered via tail vein injection in a rat model of transient middle cerebral artery occlusion (tMCAO) to assess targeting efficiency and therapeutic effects. RNA sequencing (RNA-seq) and western blotting were performed to identify signaling pathways involved in the protective effects of Exo-siCD151. RNA-seq identified CD151 as a key regulator of immune homeostasis in VECs. Following systemic administration, Exo-siCD151 selectively accumulated in ischemic brain regions, demonstrated specific targeting to VECs, and effectively downregulated CD151 expression. In tMCAO rats, Exo-siCD151 significantly reduced infarct volume, Evans blue extravasation, and brain edema, while improving neurological function. Both in vitro and in vivo, Exo-siCD151 partially restored immune homeostasis in VECs, as evidenced by reduced endothelial apoptosis, decreased inflammatory cytokine release and adhesion molecule expression, and increased tight junction protein levels. Mechanistically, inhibition of the MAPK/ERK signaling pathway and activation of the PI3K/AKT signaling pathway were involved in the neuroprotective effects of Exo-siCD151. As a targeted delivery platform, Exo-siCD151 downregulated CD151 expression, modulated the MAPK/ERK and PI3K/AKT signaling pathways, and restored immune homeostasis in ischemia-injured VECs, thereby alleviating BBB disruption after IS. These findings suggest that Exo-siCD151 represents a promising therapeutic strategy targeting endothelial immune homeostasis for stroke recovery. The online version contains supplementary material available at 10.1186/s12951-026-04467-2.